Pfizer Philippines forms branded generic unit; Accentia emerges from Chapter 11;

@FiercePharma: Expect drug-ad surge as warfarin rivals hit market. Article | Follow @FiercePharma

> Pfizer Philippines has put up a subsidiary that would sell "branded" generic drugs. Newly formed Pfizer Parke Davis would sell nine brands, seven of which would be oral and injectable antibiotics, starting next year, Roberto Bautista, the company's general manager, said in a press conference. Article

> Biovest International and its parent company Accentia Biopharmaceuticals said Wednesday they emerged from Chapter 11 bankruptcy. Story

> New Icon pact expands biomarker offerings. Report 

> A diabetes drug used as weight loss suppressant in France over 30 years is believed to have killed 500 people. The drug Mediator that was produced by pharmaceutical firm Servier was used by millions but was banned in November 2009 over fears it was linked to heart trouble. Item

> Scientists reach 10,000 mark in protein study. Article

> Orrin Hatch drafting new bill to create diagnostic regulatory process. News

> Amylin Pharmaceuticals and Eli Lilly today announced results from a retrospective study of nearly 375,000 Type 2 diabetes patients evaluating the incidence of events related to cardiovascular disease (CVD) and all-cause hospitalizations among initiators of BYETTA® (exenatide) injection compared to initiators of other commonly used diabetes medications. These findings were presented at the American Heart Association Scientific Sessions in Chicago. Lilly release

> Cancer vaccine developer partners up on biomarker program. Story

> Colon cancer biomarker helps demo potential of a common drug. Report

Biotech News

 @FierceBiotech: ReNeuron launches first stem cell trial for stroke. Article | Follow @FierceBiotech

 @JohnCFierce: Boston start-up Verastem lands $16M Series A. Story | Follow @JohnCFierce

> Sutro raises $36.5M Series C for protein drug work. Report 

> Forma wins $20M payout in Eisai pact. Story

> K-V gets permanent CEO. Item

> FDA panel backs Benlysta but spurs new marketing worries. Article 

Drug Delivery News

> ThermoDox a step away from orphan approval in Europe. Story

> Alkermes takes its lumps, but is still in the game. News

> Needle-free, heat-stable vaccine for developing nations. Report 

> Abuse-resistant drugs a growing niche. Article

> SurModics' revenue cold as Minnesota. Story 

> Trojan Horse breaks through blood-brain barrier. Article

Medical Devices News

> St. Jude Medical, Zonare to create intracardiac imaging device. Story 

> Genomics firm Helicos gets delisted. News

> Cancer experts question safety of preventative CT scans. Article

> Angeion announces CEO succession plan. Item 

> Hawkins: Medtronic awaits FDA's move on warning letter. Report 

> FDA looks to work with industry to solve defibrillator problems. Article 

And Finally... Canadian researchers have discovered an infectious superbug that can be deadly to people with cystic fibrosis, suggesting hospitals need to screen CF patients for the bacteria and practice stringent infection control around them. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.